In a pivotal study by Asanad et al., preclinical AD (as identified by CSF Aβ42/Tau ratios) showed significantly reduced PhNR amplitudes and delayed photopic full‐field ERG a‐/b‐wave implicit times compared to controls achieved 87% sensitivity and 82% specificity (AUC = 0.84, 95% CI: 0.72–0.95) in differentiating preclinical AD.191. The gene discussed is MAPT; the disease is Alzheimer disease.